 | • レポートコード：GIR-105X09116 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Medical Care |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、IBD（潰瘍性大腸炎＆クローン病）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。IBD（潰瘍性大腸炎＆クローン病）治療の種類別市場規模（TNF阻害剤、アミノサリチル酸、インテグリン拮抗薬、コルチコステロイド）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・IBD（潰瘍性大腸炎＆クローン病）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AbbVie、Pfizer、Janssen Biotech，Inc.（Johnson＆Johnson）、Allergan、Bausch Health Companies、Takeda Pharmaceutical Company、Novartis、Biogen ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：TNF阻害剤、アミノサリチル酸、インテグリン拮抗薬、コルチコステロイド ・用途別分析2016年-2026年：病院薬局、小売薬局、オンライン薬局 ・IBD（潰瘍性大腸炎＆クローン病）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・IBD（潰瘍性大腸炎＆クローン病）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・IBD（潰瘍性大腸炎＆クローン病）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・IBD（潰瘍性大腸炎＆クローン病）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・IBD（潰瘍性大腸炎＆クローン病）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The IBD (Ulcerative Colitis and Crohn’s Disease) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
IBD (Ulcerative Colitis and Crohn’s Disease) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
TNF Inhibitors
Aminosalicylates
Integrin Antagonists
Corticosteroids
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The key market players for global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment market are listed below:
AbbVie
Pfizer
Janssen Biotech，Inc.（Johnson＆Johnson）
Allergan
Bausch Health Companies
Takeda Pharmaceutical Company
Novartis
Biogen
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 TNF Inhibitors
1.2.3 Aminosalicylates
1.2.4 Integrin Antagonists
1.2.5 Corticosteroids
1.3 Market Analysis by Application
1.3.1 Overview: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size & Forecast
1.4.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Value (2016-2026))
1.4.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume (2016-2026)
1.4.3 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Price by Type (2016-2026) & (USD/Unit)
1.5 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Production Capacity Analysis
1.5.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Total Production Capacity (2016-2026)
1.5.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Drivers
1.6.2 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Restraints
1.6.3 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Trends Analysis
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.1.4 AbbVie IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.2.4 Pfizer IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Janssen Biotech，Inc.（Johnson＆Johnson）
2.3.1 Janssen Biotech，Inc.（Johnson＆Johnson） Details
2.3.2 Janssen Biotech，Inc.（Johnson＆Johnson） Major Business
2.3.3 Janssen Biotech，Inc.（Johnson＆Johnson） IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.3.4 Janssen Biotech，Inc.（Johnson＆Johnson） IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 Allergan
2.4.1 Allergan Details
2.4.2 Allergan Major Business
2.4.3 Allergan IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.4.4 Allergan IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Bausch Health Companies
2.5.1 Bausch Health Companies Details
2.5.2 Bausch Health Companies Major Business
2.5.3 Bausch Health Companies IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.5.4 Bausch Health Companies IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Takeda Pharmaceutical Company
2.6.1 Takeda Pharmaceutical Company Details
2.6.2 Takeda Pharmaceutical Company Major Business
2.6.3 Takeda Pharmaceutical Company IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.6.4 Takeda Pharmaceutical Company IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.7.4 Novartis IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Biogen
2.8.1 Biogen Details
2.8.2 Biogen Major Business
2.8.3 Biogen IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Product and Services
2.8.4 Biogen IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Manufacturer
3.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in IBD (Ulcerative Colitis and Crohn’s Disease) Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Manufacturer Market Share
3.4.2 Top 6 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Manufacturer Market Share
3.5 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Region
4.1.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Region (2016-2026)
4.2 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue (2016-2026)
4.3 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue (2016-2026)
4.4 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue (2016-2026)
4.5 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue (2016-2026)
4.6 Middle East and Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Type (2016-2026)
5.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Type (2016-2026)
5.3 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Application (2016-2026)
6.2 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Application (2016-2026)
6.3 Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Type (2016-2026)
7.2 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Application (2016-2026)
7.3 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Country
7.3.1 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Type (2016-2026)
8.2 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Application (2016-2026)
8.3 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Country
8.3.1 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Region
9.3.1 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Type (2016-2026)
10.2 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Application (2016-2026)
10.3 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Country
10.3.1 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Size by Country
11.3.1 Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Typical Distributors
12.3 IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 6. AbbVie IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Major Business
Table 9. Pfizer IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 10. Pfizer IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Janssen Biotech，Inc.（Johnson＆Johnson） Basic Information, Manufacturing Base and Competitors
Table 12. Janssen Biotech，Inc.（Johnson＆Johnson） Major Business
Table 13. Janssen Biotech，Inc.（Johnson＆Johnson） IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 14. Janssen Biotech，Inc.（Johnson＆Johnson） IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Allergan Basic Information, Manufacturing Base and Competitors
Table 16. Allergan Major Business
Table 17. Allergan IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 18. Allergan IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Bausch Health Companies Basic Information, Manufacturing Base and Competitors
Table 20. Bausch Health Companies Major Business
Table 21. Bausch Health Companies IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 22. Bausch Health Companies IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Takeda Pharmaceutical Company Basic Information, Manufacturing Base and Competitors
Table 24. Takeda Pharmaceutical Company Major Business
Table 25. Takeda Pharmaceutical Company IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 26. Takeda Pharmaceutical Company IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Novartis Basic Information, Manufacturing Base and Competitors
Table 28. Novartis Major Business
Table 29. Novartis IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 30. Novartis IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Biogen Basic Information, Manufacturing Base and Competitors
Table 32. Biogen Major Business
Table 33. Biogen IBD (Ulcerative Colitis and Crohn's Disease) Treatment Product and Services
Table 34. Biogen IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in IBD (Ulcerative Colitis and Crohn's Disease) Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and IBD (Ulcerative Colitis and Crohn's Disease) Treatment Production Site of Key Manufacturer
Table 40. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Region (2016-2021e) & (K Units)
Table 41. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Region (2021-2026) & (K Units)
Table 42. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 44. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 45. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 46. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Type (2021-2026) & (USD Million)
Table 48. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Type (2016-2021e) & (USD/Unit)
Table 49. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Type (2021-2026) & (USD/Unit)
Table 50. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 51. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 52. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Application (2021-2026) & (USD Million)
Table 54. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Application (2016-2021e) & (USD/Unit)
Table 55. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Application (2021-2026) & (USD/Unit)
Table 56. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2016-2021e) & (K Units)
Table 57. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2021-2026) & (K Units)
Table 58. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 60. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 61. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 62. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 63. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 64. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2016-2021e) & (K Units)
Table 65. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2021-2026) & (K Units)
Table 66. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 69. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 70. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 71. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 72. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Region (2016-2021e) & (K Units)
Table 73. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Region (2021-2026) & (K Units)
Table 74. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 77. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 78. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 79. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 80. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2016-2021e) & (K Units)
Table 81. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2021-2026) & (K Units)
Table 82. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 84. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 85. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 86. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 87. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 88. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2016-2021e) & (K Units)
Table 89. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Country (2021-2026) & (K Units)
Table 90. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2016-2021e) & (K Units)
Table 93. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Type (2021-2026) & (K Units)
Table 94. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2016-2021e) & (K Units)
Table 95. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales by Application (2021-2026) & (K Units)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Typical Distributors
Table 99. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Typical Customers
List of Figures
Figure 1. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Picture
Figure 2. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type in 2020
Figure 3. TNF Inhibitors
Figure 4. Aminosalicylates
Figure 5. Integrin Antagonists
Figure 6. Corticosteroids
Figure 7. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application in 2020
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. United States IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Canada IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Mexico IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Germany IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. France IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. United Kingdom IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Russia IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Italy IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. China IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Japan IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Korea IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. India IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Southeast Asia IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Australia IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Brazil IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Egypt IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Saudi Arabia IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. South Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Turkey IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales (2016-2026) & (K Units)
Figure 33. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Production Capacity (2016-2026) & (K Units)
Figure 34. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 35. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Drivers
Figure 36. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Restraints
Figure 37. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Trends
Figure 38. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Manufacturer in 2020
Figure 39. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Manufacturer in 2020
Figure 40. IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 41. Top 3 IBD (Ulcerative Colitis and Crohn's Disease) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 42. Top 6 IBD (Ulcerative Colitis and Crohn's Disease) Treatment Manufacturer (Revenue) Market Share in 2020
Figure 43. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Region (2016-2026)
Figure 44. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Region (2016-2026)
Figure 45. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue (2016-2026) & (USD Million)
Figure 46. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue (2016-2026) & (USD Million)
Figure 47. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue (2016-2026) & (USD Million)
Figure 48. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue (2016-2026) & (USD Million)
Figure 49. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue (2016-2026) & (USD Million)
Figure 50. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type (2016-2026)
Figure 51. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Type (2016-2026)
Figure 52. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Type (2016-2026) & (USD/Unit)
Figure 53. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 54. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Application (2016-2026)
Figure 55. Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Price by Application (2016-2026) & (USD/Unit)
Figure 56. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Country (2016-2026)
Figure 57. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Country (2016-2026)
Figure 58. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type (2016-2026)
Figure 59. North America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 60. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Country (2016-2026)
Figure 61. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Country (2016-2026)
Figure 62. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type (2016-2026)
Figure 63. Europe IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Region (2016-2026)
Figure 66. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Region (2016-2026)
Figure 67. Asia-Pacific IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 68. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Country (2016-2026)
Figure 69. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Country (2016-2026)
Figure 70. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type (2016-2026)
Figure 71. South America IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Revenue Market Share by Country (2016-2026)
Figure 74. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Type (2016-2026)
Figure 75. Middle East & Africa IBD (Ulcerative Colitis and Crohn's Disease) Treatment Sales Market Share by Application (2016-2026)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
潰瘍性大腸炎の治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum). Scope of the Re…- 潰瘍性大腸炎の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum). Scope of the Re…
- 潰瘍性大腸炎薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum). Scope of the Re…
- 潰瘍性大腸炎の薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum). Scope of the Re…
- クラッベ病治療の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…